Scarica l'app Stockscreener
1.455
4.28%
-0.065
Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie
Citizens reiterates Acrivon Therapeutics stock rating on endometrial cancer trial progress - Investing.com
[SCHEDULE 13D/A] Acriv... - Stock Titan
Research Analysts Set Expectations for ACRV Q1 Earnings - MarketBeat
If You Invested $1,000 in Acrivon Therapeutics, Inc. (ACRV) - Stock Titan
ACRV Technical Analysis & Stock Price Forecast - Intellectia AI
Aug EndMonth: What is Acrivon Therapeutics Incs 5 year growth outlook2026 Levels & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Form 4 Acrivon Therapeutics Inc For: 4 March By Investing.com - Investing.com Australia
Acrivon Therapeutics (NASDAQ:ACRV) Releases Earnings Results, Meets Estimates - MarketBeat
Oppenheimer reiterates Acrivon stock rating on endometrial cancer focus By Investing.com - Investing.com Canada
Oppenheimer reiterates Acrivon stock rating on endometrial cancer focus - Investing.com
Acrivon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Acrivon Highlights Positive ACR-368 Data and 2025 Results - TipRanks
ACRV: 52% response rate in serous endometrial cancer and robust cash reserves support ongoing growth - TradingView
BRIEF-Acrivon Therapeutics, Inc Q4 Income From Operations USD -20.116 Million - TradingView
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Acrivon Therapeutics (ACRV) posts 2025 results, 52% ACR-368 response and $118.6M cash - Stock Titan
Cancer drug study posts 52% response as Acrivon adds new arm - Stock Titan
Acrivon Therapeutics 10-K: $0 Revenue, $(0.00) EPS, $77.9M Net Loss - TradingView
ACRV: Net loss narrowed to $77.9M in 2025; cash runway extends into Q2 2027 - TradingView
Oncology pipeline and AP3 proteomics strategy at Acrivon (NASDAQ: ACRV) - Stock Titan
ACRV Q4'25 Earnings: revenue estimate is 166.29K USD - TradingView
Acrivon Therapeutics (ACRV) Projected to Post Earnings on Thursday - MarketBeat
Acrivon Therapeutics, Inc. (ACRV) upgraded to buy: Here's why - MSN
Acrivon Therapeutics to Present Pre-Clinical Data on ACR-368 and ACR-2316 Synergy with ADCs and Immune Checkpoint Inhibitors at 2026 AACR Annual Meeting - geneonline.com
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at - GlobeNewswire
Cancer drug combo clears tumors in mice in Acrivon study - Stock Titan
Dow Update: Will Acrivon Therapeutics Inc benefit from green energy policiesTrade Entry Summary & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
EPS Watch: Is Acrivon Therapeutics Inc gaining market shareWatch List & Consistent Return Investment Signals - baoquankhu1.vn
Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Acrivon Therapeutics (ACRV) Stock Analysis Report | Financials & Insights - Benzinga Japan
Acrivon Therapeutics shares slide sharply following mixed oncology trial update - MSN
Gains Report: What is Acrivon Therapeutics Incs 5 year growth outlookWeekly Risk Summary & Real-Time Volume Analysis - baoquankhu1.vn
Acrivon Therapeutics, Inc. (ACRV) Presents at TD Cowen 46th Annual Health Care ConferenceSlideshow - Seeking Alpha
Acrivon Therapeutics, Inc. (ACRV) Presents at ESGO 27th Annual Congress 2026Slideshow - Seeking Alpha
Acrivon Therapeutics Highlights ACR-368’s ~50% Response in Serous Endometrial Cancer at TD Cowen Conf. - Defense World
Acrivon Therapeutics (ACRV) CAO awarded 31,900 stock options at $0.00 strike - Stock Titan
Acrivon Therapeutics (ACRV) CMO granted stock options on 174,068 shares - Stock Titan
Executive Mary Miller at Acrivon Therapeutics (ACRV) granted 129,760 options - Stock Titan
Acrivon Therapeutics (ACRV) CDO awarded option on 94,946 shares - Stock Titan
Acrivon Therapeutics (ACRV) COO receives 186,728 stock options vesting from 2027 - Stock Titan
Acrivon Therapeutics (ACRV) grants stock options to CEO and EVP - Stock Titan
ACRV Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Acrivon Therapeutics, Inc. (ACRV) Raised to Buy: Discover the Reasons - Bitget
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why - Yahoo Finance
Jefferies reiterates Acrivon Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Jefferies reiterates Acrivon Therapeutics stock rating on trial data - Investing.com
Acrivon Therapeutics (NASDAQ: ACRV) takes full control of ACR-368 OncoSignature - Stock Titan
What is HC Wainwright’s Estimate for ACRV FY2030 Earnings? - Defense World
Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Lowered by Wall Street Zen - Defense World
Acrivon Therapeutics hosts webcast on ACR-368 trial at ESGO Congress - Investing.com Australia
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon - TipRanks
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - MarketBeat
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks
Acrivon (NASDAQ: ACRV) shows ACR-368 activity in endometrial cancer - Stock Titan
Pullback Watch: Can Acrivon Therapeutics Inc expand into new marketsRate Hike & Reliable Breakout Forecasts - baoquankhu1.vn
Acrivon Therapeutics (ACRV) insiders detail RSU tax-related share withholding - Stock Titan
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - Bitget
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):